Related Experiment Video
Updated: Mar 2, 2026

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
Tolerability of Opioid Analgesia for Chronic Pain: A Network Meta-Analysis
Zengdong Meng1, Jing Yu2, Michael Acuff3
1Department of Orthopaedics, First People's Hospital of YunNan Province, YunNan, P.R. China.
Abstract:
Aim of this study was to study the tolerability of opioid analgesia by performing a network meta-analysis (NMA) of randomized-controlled trials (RCTs) which investigated effectiveness of opioids for the management of chronic pain. Research articles reporting outcomes of RCT/s comparing 2 or more opioid analgesics for the management of chronic pain were obtained by database search. Bayesian NMAs were performed to combine direct comparisons between treatments with that of indirect simulated evidence. Study endpoints were: incidence of adverse events, incidence of constipation, trial withdrawal rate, and patient satisfaction with treatment. Outcomes were also compared with conventional meta-analyses. Thirty-two studies investigating 10 opioid drugs fulfilled the eligibility criteria. Tapentadol treatment was top-ranking owing to lower incidence of overall adverse events, constipation, and least trial withdrawal rate. Tapentadol was followed by oxycodone-naloxone combination in providing better tolerability and less trial withdrawal rate. Patient satisfaction was found to be higher with oxycodone-naloxone followed by fentanyl and tapentadol. These results were in agreement with those achieved with conventional meta-analyses. Tapentadol and oxycodone-naloxone are found to exhibit better tolerability characteristics in comparison with other opioid drugs for the management of chronic pain and are associated with low trial withdrawal rate and better patient satisfaction.
Insights
This network meta-analysis found tapentadol and oxycodone-naloxone offer superior tolerability for chronic pain management. These opioid analgesics demonstrated fewer adverse events, less constipation, and lower withdrawal rates compared to other options.
Area of Science:
- Pharmacology
- Clinical Medicine
- Pain Management
Background:
- Opioid analgesics are widely used for chronic pain.
- Concerns exist regarding their tolerability and adverse event profiles.
- Comparative effectiveness data on different opioids is crucial for clinical decision-making.
Purpose of the Study:
- To evaluate and compare the tolerability of various opioid analgesics for chronic pain management.
- To synthesize evidence from randomized-controlled trials using network meta-analysis.
- To identify opioid treatments with favorable safety and satisfaction profiles.
Main Methods:
- A systematic database search identified randomized-controlled trials comparing two or more opioid analgesics.
- Bayesian network meta-analyses (NMAs) were conducted to pool direct and indirect treatment comparisons.
- Key endpoints included adverse events, constipation, trial withdrawal rates, and patient satisfaction.
Main Results:
- Tapentadol ranked highest for overall tolerability, showing lower incidence of adverse events and constipation, and the least trial withdrawal.
- Oxycodone-naloxone combination demonstrated good tolerability and low withdrawal rates.
- Patient satisfaction was highest with oxycodone-naloxone, followed by fentanyl and tapentadol.
Conclusions:
- Tapentadol and oxycodone-naloxone exhibit superior tolerability compared to other opioids for chronic pain.
- These agents are associated with reduced adverse events, constipation, and trial withdrawal.
- Improved tolerability and patient satisfaction support the use of tapentadol and oxycodone-naloxone in chronic pain management.
Related Concept Videos
Analgesia and Pain Management
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Receptors: Overview
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

